Read more: Orforglipron vs Oral Semaglutide: The Full Comparison Expert Voices on the Approval Leading clinicians have welcomed the pill's approval, with important nuances: Professor Naveed Sattar , University of Glasgow: "The approval of the once-daily oral form of Wegovy is welcome news for people living with obesity, particularly those who would prefer not to use injections." Dr Simon Cork , Anglia Ruskin University, noted that oral formulations are likely to be more attractive but reminded patients that clinical trials show "slightly inferior levels of weight loss compared to injectable forms, particularly Mounjaro." He added that without the need for complex injectable pen systems, the pill will likely be cheaper
The choice of which medication is right for you depends on many factors, including: Your insurance coverage How well you tolerate the side effects Whether you have diabetes or just obesity Your personal preferences for dosing frequency Your healthcare provider at Yorktown Health can help you decide which option fits your needs best
Researchers identified 41,222 adults with overweight or obesity who were prescribed semaglutide or tirzepatide between May 2022 and September 2023
Fortunately, medicinal plants, such as Gynostemma pentaphyllum , may activate AMPK and provide some of the same metabolic benefits as metformin (Yoo 2016)
Resources & Guidelines: ICGP Migraine Quick Reference Guide NICE CG150 HSE National Clinical Programme for Neurology WHO Global Burden of Disease Study Migraine Association of Ireland (migraine.ie) #GeneralPractice #Migraine #PrimaryCare #Headache #Health To view or add a comment, sign in " ." That was perhaps the most important thing I heard in clinic yesterday
